Kromek’s 3-year contract to supply the UK with biological threat detection systems is good validation of its technology and R&D capabilities from a high-quality customer said finnCap.
While the net present value will only be a small plus, the award underpins its existing forecasts said the broker, which included an implicit award of new contracts.
“For 2024 and 2025 it provides added clarity to forecasts, with a more visible build of revenues and profits over each year.”
Finncap’s target price remains 27p with the shares up 4% to 8.45p on the news.